Sort   by:  
 Page size 
UnknownCheckpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.

Background

Checkpoint inhibitor-induced hepatitis is an immune-related adverse event of programmed cell death protein 1 (PD-1) inhibition, cytotoxic T-lymphocyte associated 4 (CTLA-4) inhibition or the combination of both. Aim of this study was to assess whether checkpoint inhibitor-induced ...
S-EPMC8144142 | biostudies-literature
UnknownMetabolic parameters on baseline and early [<sup>18</sup>F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.

Background

[18F]FDG PET/CT plays a crucial role in evaluating cancer patients and assessing treatment response, including in BRAF-mutated melanoma. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have emerged as promising alternatives to standardized uptake value (S...
S-EPMC12119442 | biostudies-literature
UnknownOncological healthcare providers' perspectives on appropriate melanoma survivorship care: a qualitative focus group study.

Background

The increasing group of melanoma survivors reports multiple unmet needs regarding survivorship care (SSC). To optimise melanoma SSC, it is crucial to take into account the perspectives of oncological healthcare providers (HCPs) in addition to those of patients. The aim of this stu...
S-EPMC10042579 | biostudies-literature
UnknownExperiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.

Background

Immune checkpoint inhibitors (ICIs) have significantly improved the overall survival of patients with metastatic melanoma. It is unclear how the growing group of metastatic melanoma survivors resume their lives after treatment, and which needs they have regarding survivorship care...
S-EPMC9545549 | biostudies-literature
UnknownEvaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.

Background

Life expectancy of patients with metastatic castration-resistant prostate cancer (mCRPC) is still limited despite several systemic treatments. Within five years after diagnosis of primary prostate cancer, 10-20% of the patients have mCRPC and curation is not an option. Radionuclid...
S-EPMC10826262 | biostudies-literature
UnknownWhole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.
Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) enzymes mutate specific DNA sequences and hairpin-loop structures, challenging the distinction between passenger and driver hotspot mutations. Here, we characterized 115 whole genomes of metastatic urothelial carcinoma (mUC) to...
S-EPMC11019362 | biostudies-literature
UnknownA blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer.
PD1 inhibition is effective in patients with metastatic urothelial cancer (mUC), yet a large fraction of patients does not respond. In this study, we aimed to identify a blood-based immune marker associated with non-response to facilitate patient selection for anti-PD1. To this end, we quantified 18...
S-EPMC9947015 | biostudies-literature
UnknownImproving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.

Background

The prognosis of advanced melanoma patients has significantly improved over the years. We aimed to evaluate the survival per year of diagnosis.

Methods

All systemically treated patients diagnosed with advanced melanoma from 2013 to 2021 were included from the Dutch Melanoma...
S-EPMC10874714 | biostudies-literature
UnknownImproved postprocessing of dynamic glucose-enhanced CEST MRI for imaging brain metastases at 3 T.

Background

Dynamic glucose-enhanced (DGE) chemical exchange saturation transfer (CEST) has the potential to characterize glucose metabolism in brain metastases. Since the effect size of DGE CEST is small at 3 T (< 1%), measurements of signal-to-noise ratios are challenging. To improve DGE de...
S-EPMC10709288 | biostudies-literature
UnknownA prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.

Background

Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may argue against the current dosing strategies. The primary objectives were to...
S-EPMC6642527 | biostudies-literature
Sort   by:  
 Page size